A daily pill taken alongside chemotherapy has made tumours disappear entirely in one in 12 people with advanced pancreatic cancer, according to early trial results presented on Friday — and cancer charities are calling it the biggest advance against the disease in decades.
The drug, daraxonrasib, was given to 61 patients whose pancreatic cancer had already spread to other parts of the body and who had not yet had any treatment. After a typical follow-up of around 18 months, tumours had shrunk or vanished in more than six in 10 of them, and in 8.2 per cent — about one in 12 — scans could no longer find any sign of the cancer at all.
What the trial actually found
The study, known as RMC-GI-102, paired a 200mg daily tablet of daraxonrasib with two standard chemotherapy drugs, gemcitabine and nab-paclitaxel, given by infusion. The results, presented at the EORTC-NCI-AACR cancer symposium in Barcelona by lead researcher Dr Wungki Park of Memorial Sloan Kettering Cancer Center in New York, were striking across the board.
According to the figures released by the drug's maker, Revolution Medicines, tumours stopped growing in 90.2 per cent of patients. On average it took 12.8 months before the disease started growing again, and an estimated 76.6 per cent of patients were still alive a year after starting treatment. For a cancer where only around a quarter of adults diagnosed survive longer than a year, according to Cancer Research UK, those numbers stand out.
Dr Park told reporters his team could scarcely believe what they were seeing. "We actually doubted our eyes because we've never seen such a thing," he said. Asked whether the patients whose tumours had vanished could be regarded as cured, he replied: "This is the closest to cure."
Why doctors are excited — and why they're cautious
Part of the excitement is about how the drug works. Daraxonrasib switches off the RAS family of proteins — the faulty switches that tell cancer cells to keep growing. The mutated KRAS gene behind that signal is found in more than nine in 10 pancreatic tumours, and for decades scientists considered it almost impossible to block with a medicine. As Cancer Research UK's Dr Sam Godfrey put it, the new drug has found "a way of drugging the undruggable."
Michelle Mitchell, Cancer Research UK's chief executive, called the results "the biggest leap forward we've seen in decades for pancreatic cancer patients," adding that they "could offer real hope to people facing one of the deadliest and most difficult-to-treat cancers."
But every expert quoted alongside the results sounded the same note of caution. This was a small, early-phase study with no group receiving chemotherapy alone for comparison, so it cannot yet prove how much of the benefit comes from the pill itself. The results have also not yet appeared in a peer-reviewed journal, and doctors don't know how long the responses will last. Dr Madina Kara, head of research at Pancreatic Cancer UK, described it as "a small, initial study" — while adding that the results show the combination "can be effective."
What happens next
The drug is not new to regulators. Daraxonrasib, sold as Rasonque, was approved by the US Food and Drug Administration in August for patients whose cancer had already been treated, after a larger trial found it almost doubled survival compared with chemotherapy alone. The European Commission approved it for previously treated patients earlier this month.
What is new is using it as a first treatment, combined with chemotherapy from the start. A much larger randomised trial, known as RASolute 303, is now testing exactly that — daraxonrasib alone and with chemotherapy against chemotherapy alone — in patients receiving their first treatment. Until those results arrive, the combination will not be routinely available to patients.
For the roughly 11,500 people diagnosed with pancreatic cancer in the UK each year, and the many more worldwide, that wait matters. Half of people with the disease die within three months of diagnosis, according to Pancreatic Cancer UK. For the first time in a very long while, though, the direction of travel looks genuinely hopeful.
This is a developing story — the larger Phase 3 trial is still under way, and we'll update this article as its results are reported.
